Evidence map›Paper›PMID 36400286›Full record

ArticleExperimental eye research2023

Repeat Brn3a immunolabeling rescues faded staining and improves detection of retinal ganglion cells.

Ryan E Shindler, Jipeng Yue, Brahim Chaqour, Kenneth S Shindler, Ahmara G Ross

Open access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ryan E ShindlerDepartment of Ophthalmology, Scheie Eye Institute, Center for Advanced Retinal and Ocular Therapeutics, F. M. Kirby Center for Molecular Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Jipeng YueDepartment of Ophthalmology, Scheie Eye Institute, Center for Advanced Retinal and Ocular Therapeutics, F. M. Kirby Center for Molecular Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Brahim ChaqourDepartment of Ophthalmology, Scheie Eye Institute, Center for Advanced Retinal and Ocular Therapeutics, F. M. Kirby Center for Molecular Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Kenneth S ShindlerDepartment of Ophthalmology, Scheie Eye Institute, Center for Advanced Retinal and Ocular Therapeutics, F. M. Kirby Center for Molecular Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; University of Pennsylvania, Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Kenneth.Shindler@uphs.upenn.edu.
Ahmara G RossDepartment of Ophthalmology, Scheie Eye Institute, Center for Advanced Retinal and Ocular Therapeutics, F. M. Kirby Center for Molecular Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; University of Pennsylvania, Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Ahmara.Ross@pennmedicine.upenn.edu.
Penn Presbyterian Medical Center · US

Funding

Mechanism of SIRT1 Activator Mediated Neuroprotection of Retinal Ganglion CellsR01EY019014 · NEI · UNIVERSITY OF PENNSYLVANIA · PI SHINDLER, KENNETH S · 2010 to 2020
$3.7M
The Development of Gene Therapy Using SIRT1 Signaling to Treat Chronic GlaucomaK08EY030163 · NEI · UNIVERSITY OF PENNSYLVANIA · PI ROSS, AHMARA G. · 2019 to 2022
$958k
NEI NIH HHS K08 EY030163NEI NIH HHS R01 EY019014
6 · The paper itself

Abstract

Immunofluorescence is used in numerous research areas including eye research to detect specific antigens in cells and tissues. One limitation is that fluorescent signal can fade, causing detection problems if data recording was not completed in a timely manner or if additional data acquisition is required. The ability to repeat immunostaining for the same antigen after initial fluorescence has faded may require time-consuming and potentially damaging steps to remove primary antibodies. Our studies assessed whether immunofluorescence could be reapplied to previously labeled retinal ganglion cells (RGCs). To examine whether immunostaining of Brn3a, a commonly used RGC marker, could be repeated in retinas with previously faded immunostaining, retinal whole mounts were labeled with anti-Brn3a primary antibodies and green fluorescent secondary antibodies, then allowed to fade over time. Faded retinas were restained with anti-Brn3a antibody followed by secondary antibody, or with secondary antibody alone. Results show restaining with anti-Brn3a primary antibody followed by Alexa-fluor green secondary antibody is effective for RGC detection. Repeat RGC labeling improved the clarity of staining compared with original staining prior to fading, with significant reduction in the percentage of blurry/out of focus fluorescent cells (6 vs 26%); whereas, repeat application of secondary antibody alone was not effective. Preflattening retinas under a coverslip prior to initial Brn3a staining also increased the clarity of staining, and facilitated significantly more accurate automated counting of RGCs. Findings suggest Brn3a antigen remains accessible for repeat immunofluorescence labeling after original staining fades. Staining retinas after flattening tissue may enhance the clarity of staining and accuracy of automated RGC counting. Repeat immunofluorescence staining, without the need to strip off prior bound antibodies, may be useful in other tissues as well and warrants future examination.

Indexed as

RetinaRetinal Ganglion CellsFluorescent Antibody TechniqueStaining and LabelingTranscription Factor Brn-3ATranscription Factor Brn-3ABrn3a stainingImmunofluorescenceRetinal ganglion cells

Identifiers

PMID36400286
PMCPMC9839618
OpenAlexW4309338122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.